# Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

> **NCT05869162** · PHASE2 · UNKNOWN · sponsor: **Shouyao Holdings (Beijing) Co. LTD** · enrollment: 153 (estimated)

## Conditions studied

- Non-small-cell Lung Carcinoma

## Interventions

- **DRUG:** SY-3505

## Key facts

- **NCT ID:** NCT05869162
- **Lead sponsor:** Shouyao Holdings (Beijing) Co. LTD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-30
- **Primary completion:** 2025-06-10
- **Final completion:** 2025-06-10
- **Target enrollment:** 153 (ESTIMATED)
- **Last updated:** 2023-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05869162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05869162, "Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05869162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*